Health Catalyst Stock Forecast, Price & News

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Health Catalyst in the last year. There are currently 10 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Health Catalyst stock.
View analyst ratings for Health Catalyst or view top-rated stocks.

Wall Street analysts have given Health Catalyst a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Health Catalyst wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Health Catalyst is scheduled to release its next quarterly earnings announcement on Tuesday, May 11th 2021.
View our earnings forecast for Health Catalyst.

Health Catalyst, Inc. (NASDAQ:HCAT) posted its quarterly earnings results on Thursday, February, 25th. The company reported ($0.16) EPS for the quarter, topping analysts' consensus estimates of ($0.39) by $0.23. The company had revenue of $53.28 million for the quarter, compared to analyst estimates of $52.21 million. Health Catalyst had a negative net margin of 48.17% and a negative trailing twelve-month return on equity of 25.57%.
View Health Catalyst's earnings history.

Health Catalyst's stock was trading at $27.58 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, HCAT stock has increased by 70.3% and is now trading at $46.97.
View which stocks have been most impacted by COVID-19.

Health Catalyst issued an update on its FY 2021 After-Hours earnings guidance on Thursday, February, 25th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $225.1-228.1 million, compared to the consensus revenue estimate of $225.88 million.

11 brokerages have issued 12-month price objectives for Health Catalyst's shares. Their forecasts range from $36.00 to $56.00. On average, they anticipate Health Catalyst's share price to reach $45.14 in the next twelve months. This suggests that the stock has a possible downside of 3.9%.
View analysts' price targets for Health Catalyst or view top-rated stocks among Wall Street analysts.

393 employees have rated Health Catalyst CEO Dan Burton on Glassdoor.com. Dan Burton has an approval rating of 99% among Health Catalyst's employees. This puts Dan Burton in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Health Catalyst include Dada Nexus (DADA), TripAdvisor (TRIP), Chindata Group (CD), OneConnect Financial Technology (OCFT), Medallia (MDLA), HUYA (HUYA), Sabre (SABR), Magnite (MGNI), 21Vianet Group (VNET), DouYu International (DOYU), Rackspace Technology (RXT), Cardlytics (CDLX), Switch (SWCH), Pluralsight (PS) and Yalla Group (YALA).
View all of HCAT's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Health Catalyst investors own include NVIDIA (NVDA), salesforce.com (CRM), Alteryx (AYX), The Walt Disney (DIS), DocuSign (DOCU), Square (SQ), Slack Technologies (WORK), ServiceNow (NOW), Marvell Technology Group (MRVL) and PayPal (PYPL).

(HCAT) raised $129 million in an IPO on Thursday, July 25th 2019. The company issued 6,000,000 shares at a price of $20.00-$23.00 per share. Goldman Sachs, J.P. Morgan and William Blair served as the underwriters for the IPO and Piper Jaffray, Evercore ISI, SVB Leerink and SunTrust Robinson Humphrey were co-managers.

Health Catalyst trades on the NASDAQ under the ticker symbol "HCAT."

Health Catalyst's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.96%), Clearbridge Investments LLC (4.56%), Alliancebernstein L.P. (4.07%), Janus Henderson Group PLC (3.38%), Victory Capital Management Inc. (2.70%) and Riverbridge Partners LLC (2.60%). Company insiders that own Health Catalyst stock include Anita Pramoda, D Fraser Bullock, Dale Sanders, Daniel D Burton, Daniel H Orenstein, James Patrick Jr Nelli, Linda Llewelyn, Paul Horstmeier and Timothy G Ferris.
View institutional ownership trends for Health Catalyst.

HCAT stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Price T Rowe Associates Inc. MD, FIL Ltd, Monarch Partners Asset Management LLC, Victory Capital Management Inc., Sepio Capital LP, Morse Asset Management Inc, and Credit Suisse AG. Company insiders that have sold Health Catalyst company stock in the last year include Anita Pramoda, D Fraser Bullock, Dale Sanders, Daniel D Burton, Daniel H Orenstein, James Patrick Jr Nelli, Linda Llewelyn, Paul Horstmeier, and Timothy G Ferris.
View insider buying and selling activity for Health Catalyst or view top insider-selling stocks.

HCAT stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Clearbridge Investments LLC, Janus Henderson Group PLC, Laurion Capital Management LP, Ashford Capital Management Inc., Riverbridge Partners LLC, Alliancebernstein L.P., and Bellecapital International Ltd..
View insider buying and selling activity for Health Catalyst or or view top insider-buying stocks.

Shares of HCAT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of HCAT stock can currently be purchased for approximately $46.97.

Health Catalyst has a market capitalization of $2.07 billion and generates $154.94 million in revenue each year. The company earns $-60,100,000.00 in net income (profit) each year or ($1.42) on an earnings per share basis.

Health Catalyst employs 1,000 workers across the globe.

The official website for Health Catalyst is www.healthcatalyst.com.

Health Catalyst is headquartered at 3165 MILLROCK DRIVE SUITE 400, SALT LAKE CITY UT, 84121.

Health Catalyst's mailing address is 3165 MILLROCK DRIVE SUITE 400, SALT LAKE CITY UT, 84121. The company can be reached via phone at 801-708-6800 or via email at [email protected]